Greaves Daniel E, Griffiths William Jh, Lever Andrew Ml
Department of Infectious Diseases, Addenbrooke's Hospital, Cambridge, UK.
Antivir Ther. 2013;18(1):135-8. doi: 10.3851/IMP2316. Epub 2012 Aug 16.
It is recognized that iron overload is associated with excess mortality in HIV/AIDS, and that this may be due to iron acting as an HIV-1 transcriptional activator. In vitro evidence using iron chelators suggests that therapeutic iron depletion may be beneficial in HIV-1 infection. We describe the clinical course of a Caucasian man with hereditary haemochromatosis and HIV infection where a significant drop in HIV viral load accompanied venesection over an 18-month period in the absence of HAART. We propose that further research should be undertaken to explore the relationship between HIV viral load and serum iron markers in hereditary haemochromatosis, with a view to evaluating the therapeutic benefit of venesection on HIV viral load in this setting.
人们认识到，铁过载与艾滋病毒/艾滋病患者的额外死亡率相关，这可能是由于铁作为HIV-1转录激活剂所致。使用铁螯合剂的体外证据表明，治疗性铁耗竭可能对HIV-1感染有益。我们描述了一名患有遗传性血色素沉着症和HIV感染的白人男性的临床病程，在未进行高效抗逆转录病毒治疗（HAART）的情况下，在18个月的时间里，随着放血治疗，HIV病毒载量显著下降。我们建议应进一步开展研究，以探索遗传性血色素沉着症中HIV病毒载量与血清铁标志物之间的关系，以便评估在这种情况下放血治疗对HIV病毒载量的治疗益处。
